![](/images/graphics-bg.png)
Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt
المؤلفون المشاركون
al-Kinaai, Najla
Zaghlul, Muhammad Sad
al-Zumur, Husam
Ahmad, Jihad
al-Minawi, Salma
Abd al-Wahhab, Mayy Amr
Fawzi, Muhammad
Rifat, Amal
Sulayman, Suniya
المصدر
Journal of the Egyptian National Cancer Institute
العدد
المجلد 30، العدد 1 (31 يناير/كانون الثاني 2018)، ص ص. 21-26، 6ص.
الناشر
جامعة القاهرة المعهد القومي للأورام
تاريخ النشر
2018-01-31
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Aim : The study aims to evaluate survival outcome in newly diagnosed pediatric intermediate risk neuroblastoma patients treated at the Children Cancer Hospital – Egypt and their relation to various clinical and pathological factors.
Methods : The study included stage 3 patients <1.5 years, children 1.5 years or older with stage 3 disease and favorable histopathological features, infants (<1 year) with International Neuroblastoma Staging System(INSS) stage 4 disease, stage 4 children 1–1.5 years with favorable biology, and infants stage 4 s (with unfavorable biologic features).
Patients received systemic chemotherapy, in the form of etoposide and carboplatin alternating with cyclophosphamide, doxorubicin and vincristine, administered at 3-week intervals, with a total of 6 or 8 cycles guided by reaching objective overall response (complete/very good partial/partial response).
Results : The study included 136 patients, 67 males and 69 females.
101 patients had abdominal primary tumors, 28 had mediastinal masss and 7 with masses in the neck; 68% were stage 3 and the remaining (n = 44) had metastatic disease.
The three-year overall survival (OS) and event-free survival (EFS) estimates were 94% ± 2% and 90.9% ± 2.5%, respectively.
OS and EFS by gender, age, pathology and INPC were all statistically not significantly different.
Moreover, OS for patients having surgery versus no surgery (inoperable residual only) was statistically significant (98.4% ± 1.6% & 88.7% ± 5.3%, respectively, p = .034).
Conclusion : A very high rate of survival is currently achievable in patients with intermediate risk neuroblastoma by chemotherapy or chemotherapy and surgery.
In addition to response, our plan is to adopt biologically-based treatment to reduce treatment-induced complications among survivors
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
al-Zumur, Husam& Ahmad, Jihad& al-Minawi, Salma& al-Kinaai, Najla& Rifat, Amal& Sulayman, Suniya…[et al.]. 2018. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute،Vol. 30, no. 1, pp.21-26.
https://search.emarefa.net/detail/BIM-788948
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
al-Zumur, Husam…[et al.]. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute Vol. 30, no. 1 (Jan. 2018), pp.21-26.
https://search.emarefa.net/detail/BIM-788948
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
al-Zumur, Husam& Ahmad, Jihad& al-Minawi, Salma& al-Kinaai, Najla& Rifat, Amal& Sulayman, Suniya…[et al.]. Survival outcome of intermediate risk neuroblastoma at children cancer hospital Egypt. Journal of the Egyptian National Cancer Institute. 2018. Vol. 30, no. 1, pp.21-26.
https://search.emarefa.net/detail/BIM-788948
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 25-26
رقم السجل
BIM-788948
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)